$LYEL
Lyell Immunopharma, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is LYEL up today? It is at $15.53 (+1.17%), and our scanner flagged it 15 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment LYEL spikes, and full due diligence on LYEL — key stats, earnings, dilution and insider activity. Free.
Get free $LYEL alerts the moment volume spikes
Our scanner flagged $LYEL 15 times in the last 30 days. Create a free account to track $LYEL, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $15.53
- Change today
- +1.17%
- Previous close
- $15.35
- 52-week range
- $10.56 – $45.00
- Market cap
- $381M
- Shares outstanding
- 24.5M SEC · as of 2026-08-03 · 20d
- Institutional own.
- 62.21%
- Total held
- 68.2%
- Tradeable float
- 7.8M 32% of shares · after 6% insiders + 62% institutions
- Short interest
- 1.2M ▲ +1% vs prior · as of 2026-07-31
- Short % of float
- 15.8%
- Days to cover
- 8.7d
- Avg daily volume
- 105K
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- XNAS
- 5m
- 0.1x
- 15m
- 0.1x
- 1h
- 0.2x
- 1D
- --
Get free LYEL + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $LYEL up today?
Here is the latest on LYEL from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for LYEL today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Latest filingSC 13G/APassive 5%+ stake updatedAug 14, 2026 · 8 days agoAnalyst data via Nasdaq. Not investment advice.
Insiders
Insiders selling0 buys, 11 sells last 3 months (6/28 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Seely Lynn Officer | Sold (automatic/other) | -390 | sold 0.5% | 73K | $6K at $14.34 | Aug 10, 26 |
Hill Stephen J. Officer | Sold (automatic/other) | -89 | sold 0.5% | 18K | $1K at $14.34 | Aug 10, 26 |
Lee Gary K. Officer | Sold (automatic/other) | -131 | sold 0.7% | 18K | $2K at $14.34 | Aug 10, 26 |
Bulis Veronica Sanchez Officer | Sold (automatic/other) | -621 | sold 4.0% | 15K | $9K at $14.34 | Aug 10, 26 |
Innovative Cellular Therapeutics Holdings Ltd Beneficial Owner (10%) | Sold (automatic/other) | -39K 0.2% of company | sold 1.3% | 2.82M | n/a | Jul 27, 26 |
Innovative Cellular Therapeutics Holdings Ltd Beneficial Owner (10%) | Sold (automatic/other) | -44K 0.2% of company | sold 1.6% | 2.77M | n/a | Jul 27, 26 |
Innovative Cellular Therapeutics Holdings Ltd Beneficial Owner (10%) | Sold (automatic/other) | -10 | sold <0.1% | 2.86M | $137 at $13.70 | Jul 17, 26 |
Innovative Cellular Therapeutics Holdings Ltd Beneficial Owner (10%) | Sold (automatic/other) | -10 | sold <0.1% | 2.86M | $137 at $13.73 | Jul 16, 26 |
Innovative Cellular Therapeutics Holdings Ltd Beneficial Owner (10%) | Sold (automatic/other) | -76K 0.3% of company | sold 2.6% | 2.86M | n/a | Jun 29, 26 |
Innovative Cellular Therapeutics Holdings Ltd Beneficial Owner (10%) | Sold (automatic/other) | -67K 0.3% of company | sold 2.2% | 2.93M | n/a | Jun 15, 26 |
Shook David Officer | Sold (automatic/other) | -2K | sold 8.6% | 21K | $25K at $12.64 | Jun 10, 26 |
Bulis Veronica Sanchez Officer | Sold (automatic/other) | -217 | sold 1.4% | 15K | $4K at $18.91 | May 11, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfRecent share offering + active shelf on file — the company raised capital and can raise more. If $LYEL runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 1,900,000 new shares · About $35.0M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$LYEL Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$LYEL Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Stocks similar to LYEL
Comparable names in pharmaceutical preparations, closest in size first.
LYEL stock FAQ
Why is $LYEL up today?
Here is the latest on LYEL from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for LYEL today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the LYEL stock price today?
LYEL last traded at $15.53, up 1.17% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live LYEL alerts?
The LYEL Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged LYEL 15 times in the last 30 days.
What exchange is LYEL on?
LYEL (Lyell Immunopharma, Inc. Common Stock) trades on XNAS, with a market cap of about $381M in the PHARMACEUTICAL PREPARATIONS sector.
Is LYEL good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge LYEL for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.